DR. MUDUSSARA ASAD KHAN MD NPI 1821290362

NPI Details

DR. Mudussara Asad Khan, MD is a medical oncology internal medicine in Daytona Beach, FL with 24 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Mudussara Asad Khan, MD NPI is 1821290362. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: BARNES MEDICAL COLLEGE
Graduation Year:2002

The provider's business location address is:

224 MEMORIAL MEDICAL PKWY
SUITE 300
DAYTONA BEACH, FL
ZIP 32117-122
Phone: (386) 231-4060
Fax: (386) 615-9119

The NPI 1821290362 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Ferritin (blood protein) level (HCPCS:82728)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Iron level (HCPCS:83540)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection of drug or substance into vein (HCPCS:96374)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Protein measurement, serum (HCPCS:84165)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Folic acid level, serum (HCPCS:82746)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Blood test, clotting time (HCPCS:85610)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Automated urinalysis test (HCPCS:81003)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Magnesium level (HCPCS:83735)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Erythropoietin (protein) level (HCPCS:82668)
• Hemoglobin analysis and measurement, electrophoresis (HCPCS:83020)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Haptoglobin (serum protein) level (HCPCS:83010)

The enumeration date for this NPI number is 6/5/2007 and was last updated on 8/9/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.